Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients

J Neuroimmunol. 2005 Jun;163(1-2):190-4. doi: 10.1016/j.jneuroim.2005.02.013. Epub 2005 Apr 13.

Abstract

To evaluate the potential role of the uPAR/uPA/PAI-1 system in HIV-induced blood-brain-barrier (BBB) disruption, CSF uPA-dependent plasminogen activation (PdPA) was analyzed by casein zymography, and CSF protein levels of all three molecules were measured by ELISA. CSF uPAR, but not uPA, PAI-1, or PdPA levels was significantly increased in neurologically compromised HIV+ patients. Only individual patients with severe AIDS dementia complex had increased levels of uPA (but not PAI-1) which fell upon initiation of antiretroviral therapy. The levels of all three molecules did not correlate with the CSF to serum albumin ratio suggesting not an important role in HIV-induced BBB disruption.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Dementia Complex / cerebrospinal fluid
  • AIDS Dementia Complex / enzymology
  • AIDS Dementia Complex / immunology
  • CD4 Lymphocyte Count
  • HIV Infections / cerebrospinal fluid*
  • HIV Infections / enzymology
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV-1*
  • Hemagglutination Inhibition Tests
  • Humans
  • Plasminogen Activator Inhibitor 1 / cerebrospinal fluid*
  • Receptors, Cell Surface / blood
  • Receptors, Cell Surface / metabolism*
  • Receptors, Urokinase Plasminogen Activator
  • Serum Albumin / cerebrospinal fluid
  • Solubility
  • Urokinase-Type Plasminogen Activator / cerebrospinal fluid*
  • Viral Load

Substances

  • PLAUR protein, human
  • Plasminogen Activator Inhibitor 1
  • Receptors, Cell Surface
  • Receptors, Urokinase Plasminogen Activator
  • Serum Albumin
  • Urokinase-Type Plasminogen Activator